Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7415-7424
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7415
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7415
Table 1 Baseline clinicopathological characteristics of hepatocellular carcinoma patients, stratified by microvascular invasion status and use of postoperative adjuvant transcatheter arterial chemoembolization n (%)
No MVI (n = 259) | MVI (n = 260) | ||||||
Characteristic | Category | No TACE (n = 187) | TACE (n = 72) | P | No TACE (n = 174) | TACE (n = 86) | P |
Age (yr) | ≤ 60 | 146 (78.1) | 65 (90.3) | 0.024 | 140 (80.5) | 73 (84.9) | 0.383 |
> 60 | 41 (21.9) | 7 (9.7) | 34 (19.5) | 13 (15.1) | |||
Sex | Female | 29 (15.5) | 9 (12.5) | 0.540 | 24 (13.8) | 11 (12.8) | 0.824 |
Male | 158 (84.5) | 63 (87.5) | 150 (86.2) | 75 (87.2) | |||
HBsAg | Negative | 19 (10.2) | 6 (8.3) | 0.656 | 18 (10.3) | 14 (16.3) | 0.171 |
Positive | 168 (89.8) | 66 (91.7) | 156 (89.7) | 72 (83.7) | |||
Total bilirubin, μmol/L | 11 (3-118.3) | 11.2 (4.9-33.2) | 0.423 | 11.2 (2.8-30.9) | 11.75 (5.1-33.1) | 0.330 | |
Prothrombin time (s) | 13.10 ± 1.18 | 13.55 ± 1.21 | 0.006 | 13.31 ± 1.38 | 13.31 ± 1.22 | 0.978 | |
AFP (ng/mL) | ≤ 400 | 128 (68.4) | 44 (61.1) | 0.263 | 89 (51.1) | 49 (57.0) | 0.376 |
> 400 | 59 (31.6) | 28 (38.9) | 85 (48.9) | 37 (43.0) | |||
HBV-DNA (IU/mL) | ≤ 104 | 95 (50.8) | 43 (59.7) | 0.197 | 89 (51.1) | 52 (60.5) | 0.156 |
> 104 | 92 (49.2) | 29 (40.3) | 85 (48.9) | 34 (39.5) | |||
Pathology data | |||||||
Size of largest tumor (cm) | ≤ 5 | 121 (64.7) | 38 (52.8) | 0.077 | 76 (43.7) | 41 (47.7) | 0.542 |
> 5 | 66 (35.3) | 34 (47.2) | 98 (56.3) | 45 (52.3) | |||
No. of nodules | Single | 155 (82.9) | 62 (86.1) | 0.528 | 137 (78.7) | 73 (84.9) | 0.237 |
Multiple | 32 (17.1) | 10 (13.9) | 37 (21.3) | 13 (15.1) | |||
Differentiation | Edmondson 1-2 | 129 (69) | 37 (51.4) | 0.008 | 91 (52.3) | 49 (57) | 0.477 |
Edmondson 3-4 | 58 (31) | 35 (48.6) | 83 (47.7) | 37 (43) | |||
Capsule | Complete | 143 (76.5) | 52 (72.2) | 0.478 | 105 (60.3) | 51 (59.3) | 0.872 |
Incomplete | 44 (23.5) | 20 (27.8) | 69 (39.7) | 35 (40.7) | |||
Cirrhosis | No | 31 (16.6) | 9 (12.5) | 0.416 | 31 (17.8) | 14 (16.3) | 0.758 |
Yes | 156 (83.4) | 63 (87.5) | 143 (82.2) | 72 (83.7) | |||
Surgical data | |||||||
Type of resection | Minor | 118 (63.1) | 48 (66.7) | 0.592 | 93 (53.4) | 47 (54.7) | 0.855 |
Major | 69 (36.9) | 24 (33.3) | 81 (46.6) | 39 (45.3) | |||
Hepatic inflow occlusion | No | 79(42.2) | 25 (34.7) | 0.268 | 53 (30.5) | 32 (37.2) | 0.275 |
Yes | 108 (57.8) | 47 (65.3) | 121 (69.5) | 54 (62.8) | |||
Child-Pugh classification | A | 180 (96.3) | 70 (97.2) | 1.000 | 172 (98.9) | 84 (97.7) | 0.601 |
B | 7 (3.7) | 2 (2.8) | 2 (1.1) | 2 (2.3) | |||
Hypersplenism | No | 169 (90.4) | 67 (93.1) | 0.497 | 155 (89.1) | 83 (96.5) | 0.043 |
Yes | 18 (9.6) | 5 (6.9) | 19 (10.9) | 3 (3.5) | |||
BCLC | 0 | 18 (9.6) | 1 (1.4) | 0.002 | 6 (3.4) | 1 (1.2) | 0.158 |
A | 151 (80.7) | 54 (75) | 121 (69.5) | 69 (80.2) | |||
B | 18 (9.6) | 17 (23.6) | 47 (27) | 16 (18.6) | |||
Recurrence | Yes | 56 (29.9) | 20 (27.8) | 0.731 | 102 (58.6) | 34 (39.5) | 0.004 |
No | 131 (70.1) | 52 (72.2) | 72 (41.4) | 52 (60.5) |
- Citation: Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol 2017; 23(41): 7415-7424
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7415.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7415